Treatment of Sū’al-Qinya (low hemoglobin level in blood) with Unani medicine Qurs-e-Zarishk

Phase 3

Not yet recruiting

• Conditions: Iron deficiency anemia secondary to blood loss (chronic),

• Registration Number: CTRI/2021/12/038795
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

This study is designed as a multicentric open trial in patients with **Sū’al-Qinya (Anemia)****.** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be treated with Unani pharmacopoeial formulation **Qurs-e-Zarishk****two tablets thrice** daily with water for 12 weeks.  The patients will be assessed at every 14 days. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be 12 weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

Composition of *QursZarishk*

| | | | |

| --- | --- | --- | --- |

|**S. No**

**Name of the Drug**

**Scientific Name**

**Quantity in gm**

|1.

Zarishk (seed)

*Berberisaristata* D.C

40

|2.

RewandChini

*Rheum emodi* Wall.

10

|3.

Gul-e-Surkh

*Rosa damascena* Mill.

10

|4.

Maghz-e-Tukhm-e-Khiyarain

*Cucumissativus* L. &

*Cucumisutilissimus*Roxb.

10

|5.

Sandal Safaid

*Santalum album* L.

10

|6.

Tukhm-e-Kasni

*Cichoriumintybus*L.

10

|7.

LukMaghsool

*Coccuslacca*

5

|8.

Asl-us-Soos

*Glycyrhizaglabra* L.

5

|9.

Gul-e-Nilofar

*Nymphae alba* L.

5

|10.

Tabasheer

*Bambusabambos*Druce.

5

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2021-12-20
• Study Start: 2021-12-27

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Female
• Target Recruitment: 110

Inclusion Criteria

• Hb% <12 gm/dl but > 8 gm/dl 2.
• Female patients in the age group of 18-65 years 3.
• With or without following complaints: Fatigue General weakness Dizziness Palpitation Breathlessness Restless leg syndrome Thumping or whooshing sound in ear Loss of appetite Chest pain Fainting.

Exclusion Criteria

• Concomitant medications or history of blood transfusion within prior to 120 days.
• Known case of any severesystemic diseases such as allergic asthma, chronic kidney diseases, auto-immune disorders(SLE, RA, ulcerative colitis), heart diseases and canceretc.
• Known cases of any other acute illness.
• Known case ofhemogolobinopathy or other red celldisordersThalassemias, sickle cell anemia, congenital dyserythropoietic anemia etc.
• History of hypersensitivity to the investigational drug or herbal drugs.
• Pregnant and nursing women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Sū’al-Qinya (Anemia)	12weeks

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	Investigations will be done at baseline and end of treatment

Trial Locations

Locations (1)

National Research Institute of Unani Medicine for Skin Disorders, Hyderabad; 🇮🇳 Hyderabad, TELANGANA, India

National Research Institute of Unani Medicine for Skin Disorders, Hyderabad

🇮🇳Hyderabad, TELANGANA, India

Dr Arzeena Jabeen

Principal investigator

9032519286

aarzu763@gmail.com